Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Gu Research Network LLC

Neither a doctor nor a teaching hospital

Research payments

$13,206,264

2,571 payments

Through program year 2025, Gu Research Network LLC is reported as receiving $13,206,264 in research payments, across 2,571 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $626,544 142
2024 Research $1,104,713 224
2023 Research $1,725,901 298
2022 Research $2,590,170 418
2021 Research $3,569,701 514
2020 Research $1,789,036 509
2019 Research $1,800,198 466

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $4,891,303 536 payments
  2. Pfizer Inc. $3,349,634 850 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $1,776,950 230 payments
  4. Medivation Inc. $1,700,068 590 payments
  5. Novartis Pharmaceuticals Corporation $558,348 3 payments
  6. Genentech, Inc. $384,568 86 payments
  7. Astellas Pharma Global Development $165,299 170 payments
  8. Dendreon Pharmaceuticals LLC $143,027 23 payments
  9. Eisai Inc. $96,602 48 payments
  10. Exelixis Inc. $88,197 16 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $3,139,594 1,002 payments
  2. A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy $2,823,717 241 payments
  3. A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer $1,667,904 190 payments
  4. A Phase 1 Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of Escalating Doses of A Vaccinebased Immunotherapy Regimen Vbir for Prostate Cancer Pf06753512 $1,548,056 264 payments
  5. A Phase 1 open-label first-in-human multi-center study to evaluate the safety tolerability pharmacokinetics and anti-tumor activity of a thorium- 227 labeled PSMA-specific antibody-chelator conjugate BAY 2315497 Injection in patients with metastatic castration resistant prostate cancer $1,389,781 37 payments
  6. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $420,098 1 payment
  7. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy $271,835 24 payments
  8. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $142,653 42 payments
  9. A Phase III of Atezolizumab Plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer $141,323 27 payments
  10. Psmafore: A Phase III, Open-Label, Multi-Center, Randomized Study Comparing 177Lu-Psma-617 VS. A Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naive Men With Progressive Metastatic Castrate Resistant Prostate Cancer $138,251 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record